Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported throug...
May 09 2017 - 7:00AM
|
WHO: |
Emergent
BioSolutions Inc. (NYSE:EBS) |
| |
|
|
WHAT: |
Ribbon-cutting and tour of expanded Emergent BioSolutions’ Center
for |
| |
Innovation in Advancement Development and Manufacturing
(CIADM), |
| |
featuring
speakers: |
| |
|
| |
Daniel J. Abdun-Nabi |
| |
President
& Chief Executive Officer, Emergent BioSolutions |
| |
|
| |
Rick A. Bright, Ph.D. |
| |
Director,
Biomedical Advanced Research and Development Authority (BARDA) |
| |
Deputy
Assistant Secretary, Office of the Assistant Secretary for
Preparedness |
| |
and
Response at the U.S. Department of Health and Human Services
(HHS) |
| |
|
| |
William H. Cole |
| |
President
& CEO, Baltimore Development Corporation |
| |
|
| |
Secretary Mike Gill |
| |
Department of Commerce, State of Maryland |
| |
|
|
WHY: |
Five
years ago, Emergent and BARDA entered into a public-private
partnership |
| |
to
establish a CIADM intended to develop and manufacture
medical |
| |
countermeasures to protect the public in health
emergencies. |
| |
|
| |
This
Wednesday, Emergent will unveil its newly expanded Baltimore
CIADM |
| |
facility
– one of only three HHS-designated Centers in the United States.
The |
| |
112,000-square-foot facility, comprised of laboratory,
manufacturing and office |
| |
space,
offers flexible manufacturing of drug substance from microbial,
cell |
| |
culture,
or viral production platforms. Its capabilities for
advanced |
| |
development and manufacturing of medical countermeasures were
designed to |
| |
help
address the U.S. government’s national security and public health
needs. |
| |
The
facility is equipped with disposable manufacturing technology to
enable |
| |
Emergent
to meet the government’s domestic preparedness priorities
and |
| |
needs on
a cost-effective, reliable and sustainable basis. |
| |
|
| |
Since its
inception, the Emergent CIADM has been awarded four task orders
by |
| |
BARDA to
develop Ebola and Marburg therapeutics and a Zika
vaccine. |
| |
Emergent
has also successfully manufactured some of its product
candidates |
| |
at the
CIADM and an Ebola vaccine candidate as part of a
third-party |
| |
collaboration. |
| |
|
|
WHERE: |
Emergent
BioSolutions Bayview Campus |
| |
5901 East
Lombard St. |
| |
Baltimore, MD 21224 |
| |
|
|
WHEN: |
Wednesday, May 10, 2017 |
| |
9 a.m. to
11 a.m. |
About Emergent BioSolutionsEmergent BioSolutions
Inc. is a global life sciences company seeking to protect and
enhance life by focusing on providing specialty products for
civilian and military populations that address accidental,
intentional, and naturally emerging public health threats. Through
our work, we envision protecting and enhancing 50 million lives
with our products by 2025. Additional information about the company
may be found at www.emergentbiosolutions.com. Follow us
@emergentbiosolu.
Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
kiefferl@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Apr 2023 to Apr 2024
